The combination of docetaxel and gemcitabine has shown significant activity in patients with metastatic breast cancer. Several studies have activity in patients of multiple lines of therapy, including patients that have been treated with prior taxane therapy. Overall responses have ranged from 30% to 79%. The major side effects of the combination chemotherapy have been neutropenia, anemia, asthenia, neuropathy, nausea, mucositis, and neutropenic fever
Advanced or metastatic breast cancer Disease that can be measured by the physician or radiologic test. May have had one chemotherapy treatment for advanced or metastatic disease. Patients may have received any prior adjuvant chemotherapy, including taxane containing regimens, provided this treatment was completed at least 6 months prior to enrollment. Patients may have received prior hormone therapy or immunotherapy.
Exclusion Criteria:
Patients with only non-measurable disease Cancer that has spread to the brain A patient who received a taxane with metastatic disease. Pregnancy Patients who received prior gemcitabine
Let’s see if you might be eligible for this study.
What is your age and gender ?
Submit
There is 1 Location for this study
See Locations Near You
For additional information regarding investigative sites for this trial, contact 1-877-CT-LILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Nashville Tennessee, , United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Katy Texas, , United States
